Corporate Profile

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

10 Years of Excellence

Ten years of innovation, collaboration and a shared commitment to improving patient care has shaped Zai Lab into a fully integrated and innovative global biopharmaceutical company.

Corporate Mission

Corporate Mission

Investor Presentation

Investor Presentation

Our Pipeline

Our Pipeline

Event Calendar

View All Events

Aug 07, 2024 8:00 AM EDT

Participants must register in advance of the conference call.

Details are as follows:

Registration Link:

All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Zai Lab Limited effected a one-to-ten share subdivision effective as of March 30, 2022 (the “Share Subdivision”). Pursuant to the Share Subdivision, each Ordinary Share of the Company was subdivided into ten ordinary shares, and each American Depositary Share (ADS) of the Company now represents ten Ordinary Shares of the Company. If you hold Ordinary Shares of the Company, such as those traded on the Hong Kong Stock Exchange, the number of Ordinary Shares that you held before the Share Subdivision has increased tenfold as a result of the Share Subdivision (therefore if you held 100 Ordinary Shares prior to the Share Subdivision, you now hold 1,000 Ordinary Shares). If you hold ADSs of the Company, such as traded through NASDAQ, the number of ADSs that you held before the Share Subdivision did not change as a result of the Share Subdivision (therefore if you held 100 ADSs prior to the Share Subdivision, you continue to hold 100 ADSs).

Investor & Media Contacts

Woman looking at phone

Investor Inquiries

Christine Chiou, SVP, Head of Investor Relations
+1 (917) 886-6929

Lina Zhang, VP, Corporate Strategy and Capital Markets

Video Camera

Media Inquiries
Shaun Maccoun, Executive Director, Global Communications
+1 (415) 317-7255
Xiaoyu Chen, Executive Director, Regional Communications